Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMCS.L Share News (MCS)

  • There is currently no data for MCS

Wednesday broker round-up

Wed, 15th Jul 2020 12:24
(Sharecast News) - Royal Dutch Shell: JP Morgan downgrades to neutral with a target price of 1,700.0p.



Ocado Group: Berenberg reiterates buy with a target price of 2,225.0p.

DFS: Berenberg reiterates buy with a target price of 210.0p.

Atalaya Mining: Canaccord reiterates buy with a target price of 220.0p.

McCarthy & Stone: Canaccord reiterates hold with a target price of 82.0p.

Ferrexpo: JP Morgan downgrades to underweight with a target price of 150.0p.

GlaxoSmithKline: Citigroup reiterates neutral.

Auto Trader Group: Deutsche Bank reiterates buy with a target price of 680.0p.

London Stock Exchange: Deutsche Bank reiterates hold with a target price of 7,700.0p.

Legal & General Group: Deutsche Bank reiterates buy with a target price of 290.0p.

Senior: Barclays reiterates underweight with a target price of 45.0p.

Marks & Spencer Group: Barclays reiterates overweight with a target price of 140.0p.

Fevertree Drinks: Liberum reiterates buy with a target price of 2,570.0p.

Big Yellow Group: Liberum reiterates hold with a target price of 1,000.0p.

Dunelm Group: Peel Hunt reiterates buy with a target price of 1,400.0p.

Related News

GSK, Hansoh's targeted cancer drug hits main survival goal in China trial
1 day ago

GSK, Hansoh's targeted cancer drug hits main survival goal in China trial

* GSK partner Hansoh reports first late-stage data ​for experimental ⁠lung cancer drug

GSK says Ris-Rez meets primary endpoint in phase 3 lung cancer trial
1 day ago

GSK says Ris-Rez meets primary endpoint in phase 3 lung cancer trial

(Alliance News) - GSK PLC on Friday announced that risvutatug rezetecan has delivered "meaningful" survival data in a "pivotal" trial for advanced or ...

GSK hails 'milestone' drug trial results in China
1 day ago

GSK hails 'milestone' drug trial results in China

(Sharecast News) - A targeted lung cancer treatment developed by GSK has shown promising results in the latest trials in China, the pharma blue chip c...

MCS.L News

Monday broker round-up
26 Oct 2020

Monday broker round-up

(Sharecast News) - Pearson: UBS upgrades to buy with a target price of 650p.

UK BROKER RATINGS SUMMARY: UBS And Barclays Raise McCarthy & Stone
26 Oct 2020

UK BROKER RATINGS SUMMARY: UBS And Barclays Raise McCarthy & Stone

UK BROKER RATINGS SUMMARY: UBS And Barclays Raise McCarthy & Stone

LONDON BRIEFING: Buoyant Hut Group Raises Annual Revenue Guidance
26 Oct 2020

LONDON BRIEFING: Buoyant Hut Group Raises Annual Revenue Guidance

LONDON BRIEFING: Buoyant Hut Group Raises Annual Revenue Guidance

Sunday newspaper round-up: Coronavirus vaccine, UK-US trade, Shell
25 Oct 2020

Sunday newspaper round-up: Coronavirus vaccine, UK-US trade, Shell

(Sharecast News) - Plans are being drawn up for frontline NHS staff to receive a coronavirus vaccine within weeks, as the Government moves to accelera...

Canaccord Genuity raises target price on McCarthy & Stone
23 Oct 2020

Canaccord Genuity raises target price on McCarthy & Stone

(Sharecast News) - Analysts at Canaccord Genuity raised their target price on homebuilder McCarthy & Stone from 80.0p to 115.0p on Friday followin...

TOP NEWS: McCarthy & Stone Accepts GBP630 Million Offer From Lone Star
23 Oct 2020

TOP NEWS: McCarthy & Stone Accepts GBP630 Million Offer From Lone Star

TOP NEWS: McCarthy & Stone Accepts GBP630 Million Offer From Lone Star

PE firm Lone Star to buy McCarthy & Stone for £630m
23 Oct 2020

PE firm Lone Star to buy McCarthy & Stone for £630m

(Sharecast News) - McCarthy & Stone has agreed to be bought by US private equity group Lone Star in a deal that values the retirement housebuilder...

LONDON MARKET PRE-OPEN: Barclays Quarterly Profit Up But No Payout Yet
23 Oct 2020

LONDON MARKET PRE-OPEN: Barclays Quarterly Profit Up But No Payout Yet

LONDON MARKET PRE-OPEN: Barclays Quarterly Profit Up But No Payout Yet